BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL; HALT-C Trial Group. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010;59:1401-9. [PMID: 20675691 DOI: 10.1136/gut.2010.207423] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Pryke R, Guha IN. Time to focus on chronic liver diseases in the community: A review of primary care hepatology tools, pathways of care and reimbursement mechanisms. J Hepatol 2022:S0168-8278(22)03146-4. [PMID: 36283499 DOI: 10.1016/j.jhep.2022.10.010] [Reference Citation Analysis]
2 Pérez-Is L, Collazos J, de la Fuente B, Morano L, Rivas-Carmenado M, Rodriguez M, Romero-Favela A, Fonseca-González GJ, Melón S, Valle-Garay E, Asensi V. 24-month decline of non-invasive liver fibrosis markers in HCV-mono and HCV/HIV coinfection after direct-acting antiviral therapy. Sci Rep 2022;12:3828. [PMID: 35264591 DOI: 10.1038/s41598-022-07548-y] [Reference Citation Analysis]
3 Sandokji I, Greenberg JH. Plasma and Urine Biomarkers of CKD: A Review of Findings in the CKiD Study. Semin Nephrol 2021;41:416-26. [PMID: 34916002 DOI: 10.1016/j.semnephrol.2021.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
4 Beste LA, Zhang X, Su GL, Van T, Ioannou GN, Oselio B, Tincopa M, Liu B, Singal AG, Zhu J, Waljee AK. Adapted time-varying covariates Cox model for predicting future cirrhosis development performs well in a large hepatitis C cohort. BMC Med Inform Decis Mak 2021;21:347. [PMID: 34903225 DOI: 10.1186/s12911-021-01711-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Reungoat E, Grigorov B, Zoulim F, Pécheur EI. Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis. Cancers (Basel) 2021;13:2270. [PMID: 34065048 DOI: 10.3390/cancers13092270] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Nishimura N, De Battista D, McGivern DR, Engle RE, Tice A, Fares-Gusmao R, Kabat J, Pomerenke A, Nguyen H, Sato S, Bock KW, Moore IN, Kleiner DE, Zamboni F, Alter HJ, Govindarajan S, Farci P. Chitinase 3-like 1 is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proc Natl Acad Sci U S A 2021;118:e2019633118. [PMID: 33888584 DOI: 10.1073/pnas.2019633118] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
7 Jin X, Fu B, Wu ZJ, Zheng XQ, Hu JH, Jin LF, Tang LL. Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China. Hepatobiliary Pancreat Dis Int 2020;19:384-9. [PMID: 32540209 DOI: 10.1016/j.hbpd.2020.05.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 El-Sheikh RM, Mansy SS, Nessim IG, Hosni HN, El Hindawi A, Hassanein MH, AbdelFattah AS. Carbamoyl phosphate synthetase 1 (CPS1) as a prognostic marker in chronic hepatitis C infection. APMIS. 2019;127:93-105. [PMID: 30698308 DOI: 10.1111/apm.12917] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lin M, Guo R, Su Z, Ke S, Zeng D. Combination leflunomide and methotrexate impedes the recovery of liver fibrosis, partly through inhibition of myeloid cell admittance. Mol Med Rep 2019;19:1622-8. [PMID: 30628675 DOI: 10.3892/mmr.2019.9821] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
10 Nielsen M, Villesen I, Sinkeviciute D, Bay-jensen A, Karsdal M. Type III collagen. Biochemistry of Collagens, Laminins and Elastin 2019. [DOI: 10.1016/b978-0-12-817068-7.00003-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Nielsen MJ, Karsdal MA, Krag A, Leeming DJ. Extracellular Matrix Remodeling with Focus on Biochemical Markers in Liver Fibrosis: Limitations and Possibilities. The Human Gut-Liver-Axis in Health and Disease 2019. [DOI: 10.1007/978-3-319-98890-0_15] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
12 Sumida Y, Kamada Y, Iwai M, Kwo PY, Yoneda M. Laboratory Tests in Liver Diseases. Diagnosis of Liver Disease 2019. [DOI: 10.1007/978-981-13-6806-6_2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Alboraie M, Schütte K, Khairy M, Elsharkawy M, Asem N, Elghamry F, Shalaby H, Esmat G, Malfertheiner P. Validation of Hepa-index as a non-invasive biomarkers panel for assessment of hepatic fibrosis in Egyptians with chronic hepatitis C. Saudi Med J 2017;38:1137-42. [PMID: 29114703 DOI: 10.15537/smj.2017.11.21220] [Reference Citation Analysis]
14 Wang L, Liu T, Zhou J, You H, Jia J. Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy. Hepatol Res 2018;48:E283-90. [PMID: 28895260 DOI: 10.1111/hepr.12982] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
15 Thandassery RB, Kaabi SA, Soofi ME, Tharian B, Singh R. Noninvasive serum models to predict significant liver related events in chronic hepatitis C. Hepatol Int 2017;11:401-8. [DOI: 10.1007/s12072-017-9800-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Collazos J, Valle-Garay E, Suárez-Zarracina T, Montes AH, Cartón JA, Asensi V. Matrix metalloproteases and their tissue inhibitors in non-alcoholic liver fibrosis of human immunodeficiency virus-infected patients. World J Virol 2017; 6(2): 36-45 [PMID: 28573088 DOI: 10.5501/wjv.v6.i2.36] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
17 Nielsen MJ, Leeming DJ, Karsdal MA, Krag A. Biomarkers of Extracellular Matrix Remodeling in Liver Diseases. Biomarkers in Disease: Methods, Discoveries and Applications 2017. [DOI: 10.1007/978-94-007-7675-3_14] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Huang Y, Adams LA, MacQuillan G, Speers D, Joseph J, Bulsara MK, Jeffrey GP. Serum models accurately predict liver-related clinical outcomes in chronic hepatitis C. J Gastroenterol Hepatol 2016;31:1736-41. [PMID: 26945918 DOI: 10.1111/jgh.13333] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
19 Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Role of inflammatory marker YKL-40 in the diagnosis, prognosis and cause of cardiovascular and liver diseases. Crit Rev Clin Lab Sci 2016;53:396-408. [PMID: 27187575 DOI: 10.1080/10408363.2016.1190683] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
20 Bernuth S, Yagmur E, Schuppan D, Sprinzl MF, Zimmermann A, Schad A, Kittner JM, Weyer V, Knapstein J, Schattenberg JM, Wörns MA, Galle PR, Zimmermann T. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Dig Liver Dis 2016;48:291-7. [PMID: 26514736 DOI: 10.1016/j.dld.2015.09.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
21 Patel K, Tillmann HL, Matta B, Sheridan MJ, Gardner SD, Shackel NA, McHutchison JG, Goodman ZD. Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers. Aliment Pharmacol Ther 2016;43:356-63. [PMID: 26560052 DOI: 10.1111/apt.13471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World J Gastroenterol 2016; 22(4): 1711-1720 [PMID: 26819535 DOI: 10.3748/wjg.v22.i4.1711] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
23 Orasan OH, Ciulei G, Cozma A, Sava M, Dumitrascu DL. Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies. Clujul Med 2016;89:24-31. [PMID: 27004022 DOI: 10.15386/cjmed-554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
24 Nielsen M, Karsdal M. Type III Collagen. Biochemistry of Collagens, Laminins and Elastin 2016. [DOI: 10.1016/b978-0-12-809847-9.00003-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
25 El-asrar MA, Elbarbary NS, Ismail EAR, Elshenity AM. Serum YKL-40 in young patients with β-thalassemia major: Relation to hepatitis C virus infection, liver stiffness by transient elastography and cardiovascular complications. Blood Cells, Molecules, and Diseases 2016;56:1-8. [DOI: 10.1016/j.bcmd.2015.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
26 Zoheiry MM, Hasan SA, El-Ahwany E, Nagy FM, Taleb HA, Nosseir M, Magdy M, Meshaal S, El-Talkawy MD, Raafat I. Serum Markers of Epithelial Mesenchymal Transition as Predictors of HCV-induced Liver Fibrosis, Cirrhosis and Hepatocellular Carcinoma. Electron Physician 2015;7:1626-37. [PMID: 26816590 DOI: 10.19082/1626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
27 Nielsen MJ, Kazankov K, Leeming DJ, Karsdal MA, Krag A, Barrera F, McLeod D, George J, Grønbæk H. Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients. PLoS One 2015;10:e0137302. [PMID: 26406331 DOI: 10.1371/journal.pone.0137302] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 5.8] [Reference Citation Analysis]
28 Torok NJ, Dranoff JA, Schuppan D, Friedman SL. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology 2015;62:627-34. [PMID: 25626988 DOI: 10.1002/hep.27720] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
29 Torok NJ, Dranoff JA, Schuppan D, Friedman SL. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology 2015;62:627-34. [PMID: 25626988 DOI: 10.1002/hep.27720] [Reference Citation Analysis]
30 Neuman MG, Cohen LB, Nanau RM. Hyaluronic acid as a non-invasive biomarker of liver fibrosis. Clin Biochem. 2016;49:302-315. [PMID: 26188920 DOI: 10.1016/j.clinbiochem.2015.07.019] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 7.4] [Reference Citation Analysis]
31 European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237-64. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 1128] [Cited by in F6Publishing: 1122] [Article Influence: 141.0] [Reference Citation Analysis]
32 Konerman MA, Zhang Y, Zhu J, Higgins PD, Lok AS, Waljee AK. Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data. Hepatology 2015;61:1832-41. [PMID: 25684666 DOI: 10.1002/hep.27750] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
33 Castera L. Non-invasive diagnosis tests. Cirrhosis: A practical guide to management 2015. [DOI: 10.1002/9781118412640.ch06] [Reference Citation Analysis]
34 Chen CJ, Lee MH, Liu J, Yang HI. Hepatocellular carcinoma risk scores: ready to use in 2015? Hepat Oncol 2015;2:1-4. [PMID: 30190979 DOI: 10.2217/hep.14.32] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
35 Nielsen MJ, Leeming DJ, Karsdal MA, Krag A. Biomarkers of Extracellular Matrix Remodeling in Liver Diseases. Biomarkers in Disease: Methods, Discoveries and Applications 2015. [DOI: 10.1007/978-94-007-7742-2_14-1] [Reference Citation Analysis]
36 Campana L, Iredale J. Matrix Metalloproteinases and Their Inhibitors. Stellate Cells in Health and Disease 2015. [DOI: 10.1016/b978-0-12-800134-9.00007-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
37 Scott R, Guha IN. Non-invasive monitoring of liver fibrosis. British Medical Bulletin 2014;112:97-106. [DOI: 10.1093/bmb/ldu031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
38 Konerman MA, Yapali S, Lok AS. Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progression. Aliment Pharmacol Ther 2014;40:863-79. [PMID: 25164152 DOI: 10.1111/apt.12921] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
39 Busk TM, Bendtsen F, Nielsen HJ, Jensen V, Brünner N, Møller S. TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. Scand J Gastroenterol 2014;49:1103-10. [PMID: 25048331 DOI: 10.3109/00365521.2014.934910] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
40 Cequera A, García de León Méndez M. Biomarkers for liver fibrosis: Advances, advantages and disadvantages. Revista de Gastroenterología de México (English Edition) 2014;79:187-99. [DOI: 10.1016/j.rgmxen.2014.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
41 Fernández-Yunquera A, Ripoll C, Bañares R, Puerto M, Rincón D, Yepes I, Catalina V, Salcedo M. Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. World J Transplant 2014; 4(2): 133-140 [PMID: 25032102 DOI: 10.5500/wjt.v4.i2.133] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
42 Cequera A, García de León Méndez MC. [Biomarkers for liver fibrosis: advances, advantages and disadvantages]. Rev Gastroenterol Mex 2014;79:187-99. [PMID: 24954541 DOI: 10.1016/j.rgmx.2014.05.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
43 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
44 Snow KK, Bell MC, Stoddard AM, Curto TM, Wright EC, Dienstag JL. Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials 2014;15:159. [PMID: 24886378 DOI: 10.1186/1745-6215-15-159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
45 Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L'Italien G, Chen CJ; R.E.V.E.A.L.-HCV Study Group. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One 2014;9:e94760. [PMID: 24801353 DOI: 10.1371/journal.pone.0094760] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L’Italien G, Chen CJ. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One. 2014;9:e94760. [PMID: 24801353 DOI: 10.1371/journal.pone.0094760] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
47 Tuten A, Kucur M, Imamoglu M, Oncul M, Acikgoz AS, Sofiyeva N, Ozturk Z, Kaya B, Oral E. Serum YKL-40 levels are altered in endometriosis. Gynecol Endocrinol 2014;30:381-4. [PMID: 24533749 DOI: 10.3109/09513590.2014.887671] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
48 Tao H, Yang J, Shi K, Huang C, Zhang L, Lv X, Li J. The significance of YKL-40 protein in liver fibrosis. Inflamm Res 2014;63:249-54. [DOI: 10.1007/s00011-013-0698-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
49 Holmgaard DB, Mygind LH, Titlestad IL, Madsen H, Pedersen SS, Johansen JS, Pedersen C. Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. BMC Pulm Med 2013;13:77. [PMID: 24373580 DOI: 10.1186/1471-2466-13-77] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
50 Feier D, Balassy C, Bastati N, Stift J, Badea R, Ba-Ssalamah A. Liver fibrosis: histopathologic and biochemical influences on diagnostic efficacy of hepatobiliary contrast-enhanced MR imaging in staging. Radiology. 2013;269:460-468. [PMID: 23878281 DOI: 10.1148/radiol.13122482] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 7.0] [Reference Citation Analysis]
51 Shao R. YKL-40 acts as an angiogenic factor to promote tumor angiogenesis. Front Physiol 2013;4:122. [PMID: 23755018 DOI: 10.3389/fphys.2013.00122] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 6.2] [Reference Citation Analysis]
52 Peters L, Mocroft A, Soriano V, Rockstroh J, Rauch A, Karlsson A, Knysz B, Pradier C, Zilmer K, Lundgren JD. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. PLoS One. 2013;8:e64283. [PMID: 23724041 DOI: 10.1371/journal.pone.0064283] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
53 Cassol E, Misra V, Holman A, Kamat A, Morgello S, Gabuzda D. Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors. BMC Infect Dis 2013;13:203. [PMID: 23641933 DOI: 10.1186/1471-2334-13-203] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 9.0] [Reference Citation Analysis]
54 Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest. 2013;123:1887-1901. [PMID: 23635787 DOI: 10.1172/jci66028] [Cited by in Crossref: 435] [Cited by in F6Publishing: 461] [Article Influence: 43.5] [Reference Citation Analysis]
55 Bhogal H, Sterling RK. Staging of liver disease: which option is right for my patient? Infect Dis Clin North Am. 2012;26:849-861. [PMID: 23083819 DOI: 10.1016/j.idc.2012.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
56 Pawlak K, Rozkiewicz D, Mysliwiec M, Pawlak D. YKL-40 in hemodialyzed patients with and without cardiovascular complications – The enhancement by the coexistence of the seropositivity against hepatitis C virus infection. Cytokine 2013;62:75-80. [DOI: 10.1016/j.cyto.2013.02.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
57 Schmidt IM, Hall IE, Kale S, Lee S, He CH, Lee Y, Chupp GL, Moeckel GW, Lee CG, Elias JA, Parikh CR, Cantley LG. Chitinase-like protein Brp-39/YKL-40 modulates the renal response to ischemic injury and predicts delayed allograft function. J Am Soc Nephrol 2013;24:309-19. [PMID: 23291472 DOI: 10.1681/ASN.2012060579] [Cited by in Crossref: 87] [Cited by in F6Publishing: 88] [Article Influence: 8.7] [Reference Citation Analysis]
58 Mygind ND, Iversen K, Køber L, Goetze JP, Nielsen H, Boesgaard S, Bay M, Johansen JS, Nielsen OW, Kirk V, Kastrup J. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. J Intern Med 2013;273:205-16. [PMID: 23140269 DOI: 10.1111/joim.12006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
59 Jensen P, Wiell C, Milting K, Poggenborg R, Østergaard M, Johansen J, Skov L. Plasma YKL-40: a potential biomarker for psoriatic arthritis?: Plasma YKL-40 in psoriasis and psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology 2013;27:815-9. [DOI: 10.1111/j.1468-3083.2012.04570.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
60 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012;142:1293-1302.e4. [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017] [Cited by in Crossref: 436] [Cited by in F6Publishing: 463] [Article Influence: 39.6] [Reference Citation Analysis]
61 Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS; HALT-C Trial Group. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int 2012;32:665-74. [PMID: 22103814 DOI: 10.1111/j.1478-3231.2011.02686.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
62 Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC; HALT-C Trial Group. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology 2012;55:1019-29. [PMID: 22030902 DOI: 10.1002/hep.24752] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
63 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 117] [Cited by in F6Publishing: 146] [Article Influence: 10.6] [Reference Citation Analysis]
64 Sjöwall C, Cardell K, Boström EA, Bokarewa MI, Enocsson H, Ekstedt M, Lindvall L, Frydén A, Almer S. High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. Hum Immunol. 2012;73:382-388. [PMID: 22333691 DOI: 10.1016/j.humimm.2012.01.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
65 Calès P, Zarski JP, Chapplain JM, Bertrais S, Sturm N, Michelet C, Babany G, Chaigneau J, Eddine Charaf M; multicentric groups (Fibrosys, ANRS HC 12, Fibrostop). Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry. J Viral Hepat 2012;19:e143-53. [PMID: 22239512 DOI: 10.1111/j.1365-2893.2011.01531.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
66 Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther 2012;35:92-104. [PMID: 22035045 DOI: 10.1111/j.1365-2036.2011.04897.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
67 Banaudha KK, Verma M. The role of microRNAs in the management of liver cancer. Methods Mol Biol 2012;863:241-51. [PMID: 22359297 DOI: 10.1007/978-1-61779-612-8_14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
68 Crespo G, Martinez SM, Forns X. Assessing the Progression of Chronic HCV to Cirrhosis. Chronic Hepatitis C Virus 2012. [DOI: 10.1007/978-1-4614-1192-5_3] [Reference Citation Analysis]
69 Papastergiou V, Tsochatzis E, Burroughs AK. Non-invasive assessment of liver fibrosis. Ann Gastroenterol 2012;25:218-31. [PMID: 24714123] [Reference Citation Analysis]
70 Gupta RK, Gupta GS. Chi-Lectins: Forms, Functions and Clinical Applications. Animal Lectins: Form, Function and Clinical Applications 2012. [DOI: 10.1007/978-3-7091-1065-2_19] [Reference Citation Analysis]
71 St. John TM. Chronic Hepatitis. Integrative Medicine 2012. [DOI: 10.1016/b978-1-4377-1793-8.00019-4] [Reference Citation Analysis]
72 Schuppan D, Pinzani M. Anti-fibrotic therapy: lost in translation? J Hepatol 2012;56 Suppl 1:S66-74. [PMID: 22300467 DOI: 10.1016/S0168-8278(12)60008-7] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 7.4] [Reference Citation Analysis]
73 Mcmahon BJ, Simons BC, Livingston SE. Update on Diagnosis and Treatment within the Four Clinical Phases of Chronic Hepatitis B Infection. Curr Hepatitis Rep 2011;10:229-234. [DOI: 10.1007/s11901-011-0110-6] [Reference Citation Analysis]
74 Rath T, Roderfeld M, Güler C, Wenzel C, Graf J, Beitinger F, Roeb E, Zachoval R. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scand J Gastroenterol 2011;46:1369-80. [PMID: 21905976 DOI: 10.3109/00365521.2011.613949] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
75 Morikawa H, Kawada N. Non-invasive diagnosis of liver fibrosis. Clin J Gastroenterol 2011;4:283-91. [DOI: 10.1007/s12328-011-0248-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
76 Stibbe KJ, Verveer C, Francke J, Hansen BE, Zondervan PE, Kuipers EJ, de Knegt RJ, van Vuuren AJ. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol 2011;46:962-72. [PMID: 21623677 DOI: 10.3109/00365521.2011.574725] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
77 Nielsen KR, Steffensen R, Boegsted M, Baech J, Lundbye-Christensen S, Hetland ML, Krintel SB, Johnsen HE, Nyegaard M, Johansen JS. Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects. Arthritis Res Ther 2011;13:R109. [PMID: 21714862 DOI: 10.1186/ar3391] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
78 Clark PJ, Patel K. Noninvasive tools to assess liver disease. Curr Opin Gastroenterol 2011;27:210-6. [PMID: 21248634 DOI: 10.1097/MOG.0b013e328343e9a3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
79 Nielsen AR, Plomgaard P, Krabbe KS, Johansen JS, Pedersen BK. IL-6, but not TNF-α, increases plasma YKL-40 in human subjects. Cytokine. 2011;55:152-155. [PMID: 21478032 DOI: 10.1016/j.cyto.2011.03.014] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 5.3] [Reference Citation Analysis]
80 Bojesen SE, Johansen JS, Nordestgaard BG. Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta 2011;412:709-12. [PMID: 21272568 DOI: 10.1016/j.cca.2011.01.022] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 7.1] [Reference Citation Analysis]